Atai Life Sciences (Nasdaq: ATAI) posted a $39 million net loss for the fourth quarter of 2024 but announced Monday that it boosted its financial position with a recent equity offering that extends its operational runway into 2027.
The clinical-stage company, which mainly focuses on developing psychedelic-based treatments for mental health…
Please login to read all 428 words.
